Long-Term Decrease in VLA-4 Expression and Functional Impairment of Dendritic Cells during Natalizumab Therapy in Patients with Multiple Sclerosis

Natalizumab and Progressive Multifocal Leukoencephalopathy

(2010) Clemens Warnke et al.   ARCHIVES OF NEUROLOGY

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers

(2009) M. Khademi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Clinical response to interferon-β-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells

(2009) Clara de Andrés et al.   JOURNAL OF NEUROIMMUNOLOGY

α4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions

(2009) Shumei Man et al.   JOURNAL OF NEUROIMMUNOLOGY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab

(2009) Yiping Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

β1integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity

(2009) Martina Bauer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab

(2008) Maria del Pilar Martin   ARCHIVES OF NEUROLOGY

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

(2008) F. Zohren et al.   BLOOD

New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab

(2008) Hans-Peter Hartung   LANCET NEUROLOGY

Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1

(2008) A Sanna et al.   Multiple Sclerosis Journal

Early relapses after the first dose of natalizumab in active multiple sclerosis patients

(2008) D Centonze et al.   Multiple Sclerosis Journal

Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2008) D. S. Goodin et al.   NEUROLOGY